Raidium
Raidium is developing a foundation model for precision medicine in radiology, aiming to advance access to imaging biomarkers through an AI-native interactive platform. Their approach utilizes multimodal input capabilities and self-supervised learning, allowing the model to perform various downstream medical analyses beyond a single task. The company was founded by Paul Hérent (CEO) and Pierre Manceron (CSO), both with prior experience at Owkin. Raidium has secured significant funding, including a €16 million seed round, and has received recognition such as the AMGEN Golden Ticket and being named a Future 40 startup by Station F. Their core product, ONCOPILOT, is a promptable CT foundation model for solid tumor evaluation, demonstrating state-of-the-art performance in tumor segmentation and radiologist-level precision in RECIST 1.1 evaluations.
Raidium
Raidium is developing a foundation model for precision medicine in radiology, aiming to advance access to imaging biomarkers through an AI-native interactive platform. Their approach utilizes multimodal input capabilities and self-supervised learning, allowing the model to perform various downstream medical analyses beyond a single task. The company was founded by Paul Hérent (CEO) and Pierre Manceron (CSO), both with prior experience at Owkin. Raidium has secured significant funding, including a €16 million seed round, and has received recognition such as the AMGEN Golden Ticket and being named a Future 40 startup by Station F. Their core product, ONCOPILOT, is a promptable CT foundation model for solid tumor evaluation, demonstrating state-of-the-art performance in tumor segmentation and radiologist-level precision in RECIST 1.1 evaluations.
TL;DR
What they do: Building an AI-native PACS viewer and a multimodal radiology foundation model for precision medicine
Flagship product: ONCOPILOT — a promptable CT foundation model for solid tumor evaluation
Founders: Paul Hérent (CEO) and Pierre Manceron (CSO)
Recent funding: Reported ~€16M seed round (Nov 2024); investors include Kurma Partners and Newfund
Location / industry: France-based; Biotechnology / Medtech (radiology AI)
Company Overview
Problem Domain
Radiology workflows, tumor segmentation, RECIST 1.1 evaluations, and imaging-biomarker extraction for precision medicine.
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
€16,000,000
Seed round reported November 2024 with participation from Newfund and other investors
Investor Signal
“Investors reported include Kurma Partners, Newfund, Galion.exe, Founders Future, Techmind, Debiopharm Group and the European Innovation Council (EIC)”